App-Quantinova.ai

Checkmate 577: Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC).

Eric Van Cutsem - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Nivolumab

Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC).

Ghassan K. Abou-Alfa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.

T.R. Jeffry Evans - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Advanced biliary tract carcinoma

N/A

Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

Josep Tabernero - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Erbitux

Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).

Gayathri Anandappa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Tumor bulk as a prognostic biomarker and predictor of benefit from anti-EGFR therapy in patients with metastatic colorectal cancer: Analysis of 476 patients from the ARCAD Clinical Trials Program.

Benjamin Adam Weinberg - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/ang2-blocking nanobody.

Maen A. Hussein - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

N/A

Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).

Talia Golan - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Olaparib

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

Lawrence Howard Schwartz - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Olaparib

Longitudinal evaluation of quality of life (QoL) in patients (Pts) with FGFR2-driven cholangiocarcinoma (CCA) treated with pemigatinib.

Juan W. Valle - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.

Milind M. Javle - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Gemcitabine

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.

Luis Villanueva - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Pembrolizumab

Global BRAF testing practices in metastatic colorectal cancer.

Scott Kopetz - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Carlos Gomez-Roca - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

A phase II open-label study in adult and adolescent patients (pts) with advanced solid tumors harboring fibroblast growth factor receptor (FGFR) gene alterations.

Shubham Pant - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial.

Hedy L. Kindler - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic pancreatic adenocarcinoma

Olaparib

Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.

Avani Athauda - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Avelumab

Phase Ib/II open-label, randomized evaluation of efficacy and safety of atezolizumab plus isatuximab versus regorafenib in MORPHEUS-colorectal cancer.

Jayesh Desai - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Atezolizumab

Selecting the optimal neoadjuvant treatment approach based on the risk of an involved surgical margin in locally advanced adenocarcinoma of the esophagus and esophagogastric junction.

Tim Spencer - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Carboplatin

Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).

Mairead Geraldine McNamara - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Filters

45280 Abstracts